PLX Financial Facts
COST OF REVENUES: -4.25MRESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
See Full Income Statement
Total liabilities: 85.58M
Inventories: 4.86M
See Full Balance Sheet
Protalix Biotherapeutics, Inc. (PLX) Earnings
|
Expand Research on PLX
| Next EPS Date | 5/8/24 | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +11.7% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -3.3% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/7/23 | Q223 | -$0.16 | N/A | N/A | $24.84M | $10.22M | N/A |  | | Details | |
| 2/27/23 | Q422 | -$0.22 | -$0.15 | -$0.07 | $62.89M | $6.12M | N/A | | | Details | |
| 6/1/20 |  |
Q120 | $0.10 | -$0.30 | +$0.40 | $21.65M | $6.6M | N/A | | | Details |
| 5/16/22 | |
Q122 | -$0.05 | N/A | N/A | $16.1M | $15.5M | N/A | | | Details |
| 8/10/20 | |
Q220 | -$0.13 | -$0.20 | +$0.07 | $10.97M | $10.87M | N/A | | | Details |
| 11/14/22 | Q322 | -$0.07 | -$0.15 | +$0.08 | $5.4M | $5.7M | N/A | | | Details | |
| 8/10/15 | Q215 | -$0.05 | N/A | N/A | N/A | N/A | N/A | | | Details | |
| 5/14/21 | |
Q121 | -$0.14 | -$0.17 | +$0.03 | $11.32M | $10.95M | N/A | | | Details |
